Hemispherx treats first patient with cancer drug Ampligen in Phase 2 clinical trials
Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) took a key step forward in its Phase 2 clinical trial on Wednesday after it announced that the first patient has been treated with its flagship drug Ampligen.
The study looks at the effectiveness of ampligen in combination with the drug pembrolizumab at treating ovarian cancer. It is being run out of the University of Pittsburgh Medical Center.
Shares of Hemispherx jumped 21.8% on Wednesday afternoon in New York.
Florida-based Hemispherx believes that Ampligen could have anti-viral and anti-cancer properties. Prior clinical trials of the drug looked at patients with renal cell carcinoma and malignant melanoma.
The Phase 1 initial study indicated that Ampligen is generally well-tolerated when administrated through the abdominal cavity.
The Phase 2 clinical trials are being run under the leadership of principal investigator Dr. Robert Edwards and is expected to treat 45 patients.
Related news
- Yellow Diamonds - A Gap in the Diamond market
- Coffee with Samso: Episode 1, Australian Tungsten Projects and How the Chinese Market View The Tungsten sector
- Chasing for Kryptonite, the unknown other Lithium source
- What is In-Situ Recovery? Mining in a National Park with no environmental footprint
- Buds & Duds: Cannabis stocks drop but Weekend Unlimited shares jump on CBD hemp seed news
- THC Global granted cannabis Manufacture Licence, shares surge 20%
- Emerge Gaming shares surge on partnering with VIMN Africa to develop Nickelodeon eSports platform
.jpg)